Evidence map›Paper›PMID 37142301›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Clinical Evaluation of

Liang Zhao, Xuejun Wen, Weizhi Xu, Yizhen Pang, Long Sun, Xiaoming Wu, Pengfei Xu, Jingjing Zhang, Zhide Guo, Qin Lin and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. [European journal of nuclear medicine and molecular imaging · 2025
    Trial
  3. Dual-Target Nectin-4/FAP Heterobivalent ProbeAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracerEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  12. Article
  13. Review
  14. Pilot study ofRespiratory research · 2025
    Article
  15. Review
  16. Review
  17. Clinical comprehensive evaluation of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  18. Review
  19. Design, preclinical evaluation, and first-in-human PET study of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Liang ZhaoDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Xuejun WenState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics and Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China.
Weizhi XuDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yizhen PangDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Long SunDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Xiaoming WuCollege of Nuclear Science and Technology, Harbin Engineering University, Harbin, China; and.
Pengfei XuDepartments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore.
Jingjing ZhangDepartments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore.
Zhide GuoState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics and Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China.
Qin LinDepartment of Radiation Oncology, Xiamen Key Laboratory of Radiation Oncology, Xiamen Cancer Center, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Xiaoyuan ChenDepartments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore; leochen0821@foxmail.com chen.shawn@nus.edu.sg.
Haojun ChenDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China; leochen0821@foxmail.com chen.shawn@nus.edu.sg.
First Affiliated Hospital of Xiamen University · CNNational University of Singapore · SGXiamen University · CNHarbin Engineering University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiolabeled fibroblast activation protein (FAP) inhibitors (FAPIs) and Arg-Gly-Asp (RGD) peptides have been extensively investigated for imaging of FAP- and integrin α

Indexed as

Integrin alphaVbeta3QuinolinesFibroblastsFluorodeoxyglucose F18Gallium RadioisotopesHumansLymphatic MetastasisOligopeptidesPositron-Emission TomographyPositron Emission Tomography Computed Tomographyarginyl-glycyl-aspartic acidFluorodeoxyglucose F18Gallium RadioisotopesIntegrin alphaVbeta3OligopeptidesQuinolinescancer-associated-fibroblastsfibroblast activation proteinheterodimerintegrin αvβ3PET

Identifiers

PMID37142301
PMCPMC10394316
OpenAlexW4368363508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.